For decades, high-throughput genetic screens for essential genes were costly and slow in mammalian genomes. With CRISPR-Cas9 technology (Clustered Regularly Interspaced Short Palindromic Repeats -CRISPR-associated protein 9) and large panels of cell lines now available, tissue-specific sensitivities and pathogenic mutations can be tested at scales never before attempted (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Genetic vulnerabilities can now be demonstrated through direct perturbation, rather than relying upon indirect associations through population enrichment studies or expression levels. Phenotypic evaluation across a diverse panel of cell lines allows the early identification of potential tissue-specific side effects, and the isolation of genes essential only to a pathologic biological process. These subtypespecific genetic vulnerabilities are ideal targets for novel therapies guided by personalized genomics.
CRISPR knockout screening offers excellent sensitivity when compared to previous work using RNAi, thanks to CRISPR's effectiveness at disrupting targeted elements and reduced off-target effects (11) (12) (13) . The CRISPR-Cas9 knockout system in particular allows the design of extremely flexible and high-throughput negative selection assays in human cell lines (Fig. 1) . In a typical screen, the artificially expressed Cas9 nuclease introduces a double-stranded break in native DNA, guided by homology with the separately infected single strand guide RNA (sgRNA). The cell then either inserts or deletes a small region of the flanking nucleotides, destroying the target site homology, and repairs the double-stranded break. The resulting genetic lesion disrupts the function of the targeted region. This genetically modified cell proliferates for a series of divisions until harvested by the experimentalist. Any effects on cell growth are measured by sequencing the sgRNA present in the final surviving population of cells. Lethal sgRNA constructs which have introduced a genomic lesion at a site essential for their cell line will be underrepresented in the final population in contrast to nonessential controls. Differential essentiality can be detected from different levels of sgRNA depletion between samples or panels of sample types. Many experiments evaluate the loss of cells infected with lethal sgRNA by sequencing both the initial infected and the final population of cells (14) (15) (16) (17) . Other experiments sequence only the initial pool of sgRNA constructs prior to infection (9, 18, 19) , and use the sgRNA abundances in this master library as a proxy for initial frequencies. The master library of sgRNA ranges in abundance across several orders of magnitude, and each biological replicate represents a separate infection of this master library into a new pool of cells.
Most previous methods for statistical inference have relied on summary statistics. However, the use of summary statistics ignores sources of variation unique to each experimental stage, and prohibits adaptation to variation in experimental design (illustrated in Fig. 1 ). Methods such as BAGEL, JACKS, and others rely upon the log fold change of read abundances (1, 2, (8) (9) (10) 20) . Read counts are handled equivalently whether an experiment which has sequenced the initial timepoint or only the master library; if both the master library and initial read counts are available, the user must choose one to use as a 'base'. Other methods simplify gene essentiality into a binary classification of essential or nonessential (2, 4, 21) , enabling the identification of clear outliers but neglecting signals of significant but moderate essentiality. Finally, most methods do not test for differential essentiality within sample subtypes (22, 23) (see Fig. S1 for methods comparison).
In this paper, we introduce a model for the Analysis of CRISPR-based Essentiality (ACE), a probabilistic model which allows adaptation to variations in experimental design and principled testing of differential essentiality between sample subtypes. Our approach considers each experimental phase of the CRISPR screen -the master library infection, the initial and final sequencing -as a separate probabilistic process forming a hierarchical Bayesian model. The modularity of our framework permits the analysis of a variety of CRISPR screen databases while accounting for differences in experimental design. Results are tested using both simulations and published sets of essential and nonessential genes. Using a likelihood ratio testing framework, we identify both the degree of a gene's essentiality and the significance of differences between sets of samples.
Results
We have developed a method for the Analysis of CRISPRbased Essentiality (ACE) which leverages information from all available sequenced datasets within a CRIPSR-Cas9 screen, and extracts signal attributable to samples, genes, or individual sgRNA cutting efficiency. By separately modeling each stage of the CRISPR screening process, we can both account for noise unique to this experiment, and address shifting experimental design in this developing field. ACE Model Overview. ACE exploits the orthogonal sources of information from sample-, gene-, and sgRNA-specific effects by separately inferring parameters for each (see Fig. 2 ). For every sgRNA g and sample s, users provide sequencing read counts from the master library m g and/or the initial pool of infected cells x sg , along with the sequenced sgRNA in the depleted pool y sg . Information on each sgRNA's targeted gene and efficiency features must also be provided, along with an estimated number of cells c s used in the experiment. The model returns sgRNA efficiency, gene essentiality, and the likelihood of differential essentiality between sample subtypes. Likelihood Model. . As illustrated in the graphical model shown in Fig. 2 , the structure of our likelihood model reflects the experimental design of a CRISPR-Cas9 screen. Each biological replicate s represents an independent sampling of the sgRNA g present in a fraction m g ∈ [0, 1] of the master library, conditioned upon the number of cells c s used in the assay. The edited population of cells is then sampled at initial and final timepoints, resulting in the read counts of x sg and y sg respectively. Each of these sampling processes is modeled as a Poisson distribution, resulting in the final likelihood shown in Fig. 2b . As the true abundance of cells in n sg is unknown, we sum over all possible values of n sg = [0, c s ] in the likelihood calculation. The resulting probability density function reflects the known overdispersion of count data (see Fig. S3 ). With this approach, the ACE model seeks to identify not only the essentiality per targeted element G, but also the experimental parameters unique to CRISPR-Cas9.
Gene-level Essentiality in ACE. We define essentiality φ G as the fractional depletion of cells carrying sgRNAs targeting gene G, after accounting for sgRNA-and sample-specific effects, and φ G ranges from equal to or less than 1 (fully essential). Negative values of φ, reflecting increased growth after gene loss, can also be detected (see Methods). The full likelihood of the model pools data across each gene G, each sgRNA g within each gene, and each sample s when inferring model parameters. Gene-level essentiality (φ G ≤ 1, with nonessential genes at 0) is calculated using all samples, and all sgRNAs which target gene G. Each parameter is inferred separately for computational efficiency. The abundance of sgRNA g in the depleted population of cells d sg is evaluated as a function of sgRNA efficiency g , initial infected cells n sg , and essentiality φ G ( Fig. 2b ).
Differential Essentiality Hypothesis Testing. . This probabilistic likelihood framework is used not only to estimate the essentiality of gene G, but also whether this essentiality score φ G is significantly different in different sample types. For each gene G, ACE computes the likelihood that essentiality φ G is constant across all samples. To test for differential essentiality within a sample, separate values of essentiality are estimated for the 'test' sample and for all other samples. The resulting likelihoods compared with the global essentiality likelihood in a likelihood ratio test. This approach directly tests the null hypothesis of whether a uniform essentiality best fits the data, or whether the test and control subtypes rely upon different genes for cell viability and proliferation.
Guide-specific Parameters in ACE. The essentiality of each sgRNA's target locus φ G can only be observed in successfully edited cells. We model cells infected by the sgRNA g as a mixture of effective and ineffective disruptions, with the fraction successfully disrupted described by 'efficiency' g ∈ [0, 1]. This efficiency is determined by logistic regression based on a user-defined set of features as in Methods. The efficiency of a class of sgRNA may be predicted by a number of factors, and several groups are actively investigating this area (18, (24) (25) (26) (27) . Our method estimates efficiency based on sgRNA GC content deciles, though any user-designated categorical sgRNA feature may be used (see Eq. (6)). Other common features used in sgRNA efficiency predictions include proximity to heterochromatin, number of base mismatches, and abundance of off-target sites. No matter the feature, ACE pools information across all genes and samples using logistic regression to identify the relative fraction of successful sgRNA per feature category, g , within the context of each experiment.
Sample-specific Scaling Parameters in ACE. The samplespecific scaling factors γ s and γ s affect all sgRNAs and genes within a sample. They control for the relationship between the number of cells infected, and the expected sgRNA counts in the initial and final rounds of sequencing, respectively. These scaling parameters are based on a median-of-ratios normalization which reflects the total read count in γ s , and sample-specific factors in cell growth for γ s (see Eq. (4)). For libraries with a large number of essential targets, negative controls are used in place of a median-based normalization. The final pair of sample-specific scaling parameters is independent of the genes targeted by a particular library.
Our essentiality metric φ G pools information across cell lines, and reflects the essentiality common across all samples in a subtype. Thus the panel of samples designated by the user will determine the genetic context of the gene essentiality φ G measured. When choosing a panel of samples, care must be taken to ensure the level of diversity appropriate for the biological question. A varied collection of tissue samples or cell lines is required for the identification of universally essential genes, while a set of patient-derived tissue samples is best for personalized tumor therapeutics. Samples with a genetic background different from the analyzed panel may depend on alternate pathways for cell growth and proliferation, so essentiality values must be generalized with caution.
Simulation Performance. To evaluate the ability of ACE to infer sgRNA-, sample-, and gene-specific parameters, we developed an empirical simulation method to generate read counts from a CRISPR screen with true values precisely defined. To ensure our simulated count data reflects the diversity of observed CRISPR screen data as much as possible, we developed empiriCRISPR, a simple CRISPR screen simulator that models the variation observed in a reference experiment. Our em-piriCRISPR simulation framework is independent of parameter inference with ACE, and simulates sgRNA frequencies as a series of three gamma distributions. Final sgRNA frequencies are then scaled and rounded to the user-specified total read counts. Variation and correlation between samples are simulated to match a template CRISPR screen (see Methods). As many biological hyperparameters are difficult to infer, our simulator merely reproduces the variation observed in the final count data from nonessential sgRNA in the template screen (see S 2). All nonessential sgRNA may then be simulated with userspecified effects, providing a gold-standard dataset of known parameters across a range of essentiality values. Simulating Essentiality Gold Standards. To test the capability of ACE for inferring gene essentiality within sample, we simulated a 'gold standard' gene set with empiriCRISPR. Gene essentiality can vary from targets with a complete essentiality φ G = 1 (100% loss of all associated sgRNA), to nonessential genes with φ G = 0. To ensure fairness to methods with a median-based normalization method, we simulated 3,150 genes as nonessential (φ G = 0; 60% of total genes). Three replicates were simulated with an average of 300 reads per sgRNA, with four sgRNA targeting each gene. The noise profile of our simulated counts and relative frequencies of sgRNA in the master library was designed to match the genome-wide CRISPR screens published in Martin et al. 2017 (16) , in which both the master library and initial infected sgRNA abundances were sequenced along with the depleted samples.
Identification of Essentiality Within a Sample.
We contrast ACE estimation of essentiality with results derived from the average fold changes as used in studies such as (17, 28) in Fig. 3 . ACE infers each gene's essentiality with reduced error, as shown in Fig. S4 , and offers an improved estimate of essentiality, with the median estimate closely matching simulated φ G .
Many methods do not provide an estimate of the essentiality of a gene, instead focusing on the binary question of whether or not a gene is essential. We simplified the problem of essentiality inference by simulating 300 genes at 'moderate' (φ G = 0.5) essentiality, and evaluating the ability of several methods to distinguish essential genes from nonessential controls (φ G = 0). As shown in Fig. 4 , all methods are proficient at identifying essential genes in this simulation. Fig. 4 . Binary Essential/Nonessential Classification. While ACE is designed to test for differential essentiality between samples, most methods are designed to test whether a gene is essential or nonessential within a particular sample. Results are shown for the prediction of 'essential' or 'nonessential' using different methods in a sample with 3 replicates and 300 genes simulated φ G = .5. 3,000 nonessential genes were also simulated, and used as the true positive set in the calculation of the ROC. Only initial and final read counts from the simulation were used for all methods. 'ACE' -likelihood derived from our probabilistic method, ACE. 'AFC' -z-scores calculated from averaging fold changes in sgRNA abundance (see methods). 'BAGEL' -Bayes factor for essentiality reported by the BAGEL method (2) . 'JACKS' -p-values for essentiality reported by the JACKS method (8) . Fig. 4a ROC curves for all methods at moderate (φ G = 0.5) and strong (φ G = 0.99) levels of essentiality. Fig. 4b The area under the ROC curves.
Identification of Differential Essentiality. While measures of gene essentiality φ G within a sample are helpful for identifying sets of essential genes, one advantage of using a statistical method such as ACE lies in the identification of genes with different essentiality between tissue types. These 'differentially essential' genes are vital for exploiting genetic weaknesses in a cancer subtype, or identifying which metabolic pathway a drug resistant cell line is exploiting.
To test ACE performance on the discovery of differential essentiality, we simulated a 'control' and a 'test' sample, each with three replicates. In both samples, uniformly essential control genes were simulated at strong essentiality (φ G = 0.99, 300 genes), moderate essentiality (φ G = 0.5, 300 genes), and no essentiality (φ G = 0, 3,150 genes). In contrast to this 'uniform essentiality' set, genes with differential essentiality were simulated, with essentiality φ G test = [. 2, .4, .6, .8, .99] in the test sample only (see Methods). The ability of ACE and other methods to distinguish differentially essential genes from uniformly essential and nonessential genes is shown in Fig. 5 . Using a likelihood ratio test framework, ACE can identify the probability of even moderate differential depletion for each gene, detecting 14% of genes with φ G = .4 in the test sample only ( Fig. S5 ). , and φ G = 0 in the control sample. Uniformly essential controls were simulated at nonessential (φ G = 0), moderately essential (φ G = 0.5), and strongly essential (φ G = 0.99) levels. Fig. 5a Performance identifying 300 genes depleted only in test samples; 300 genes from each of the strong, moderate, and nonessential essentiality control groups were used as true negative controls. Fig. 5b ROC curves for select levels of differential essentiality. Essentiality levels shown are present in the test sample; the same genes are nonessential in the control sample.
Our model simultaneously infers the magnitude of each gene's essentiality within the subset, the significance of that essentiality, and the likelihood that this value of essentiality is unique to the sample subset. Our model may be run with differ-ent criteria for defining a subset of interest, such as tissue type, tumor-suppressor mutation, or cancer of origin. ACE Performance on Real Data. We sought to compare the performance of ACE on sets of essential genes identified by previous studies, but a 'gold standard' set has not been established. For our reference essential set, we use 688 genes that have been classified as essential in at least two previously published reference sets as shown in Fig. 6 (1-3) . These essential genes are evaluated in published genome-wide screen data, which was also used in the development of this gene set (19) . Our nonessential controls are genes with a FPKM < 1 across all cell lines and patient samples in the ENCODE database (see Methods).
When we look at the ability of ACE to re-evaluate essential and nonessential phenotypes within this dataset, we find nonessential genes are consistently fit with lower essentiality values than the essential controls, as expected (see Fig. S6 ). 
Discussion
The rapidly evolving experimental design of CRISPR negative selection screens offers both a challenge and an opportunity for probabilistic modeling. By creating a flexible hierarchical framework, ACE hopes to capture the information specific to CRISPR assays, and provide a rigorous likelihood ratio test for identifying significantly essential genes both within and between samples.
The experimental question driving a CRISPR negative selection screen is not whether or not a gene is essential, but whether the dependencies of one sample type are the same as another's. ACE was designed to isolate these differentially depleted genes within sample subsets, and we see increased sensitivity for finding targets within our simulated data set (see Fig. 5 ). By combining orthogonal sources of information, ACE is able to identify sgRNA-, sample-, and gene-specific parameters, while providing a principled likelihood framework. This permits the experimental investigator to clearly identify targets of differential essentiality, both in certainty of the es- Fig. 7 . ACE Performance on Essential Genes. Screening data from the genomewide CRISPR screen performed by Tzelepis et. al (19) was analyzed using ACE. Shown are essential and nonessential genes (see Methods; p-values fit to ACE likelihood-ratio results using an empirical null distribution based on all nonessential genes). Likelihood of essentiality is based on the likelihood of estimated essentiality φ G compared with the likelihood a gene is nonessential ( φ G = 0). sentiality estimate and in degree of difference between test and control samples.
Simulations provide an objective gold standard to evaluate method performance. While sets of core essential genes will continue to be developed as more cell lines are screened with higher quality CRISPR libraries, simulated datasets provide a reliable ground truth. It can be difficult to estimate the false discovery rate of differential essentiality targets as few controls exist, but simulations through empiriCRISPR let us estimate a custom error rate for a particular experiment. In addition to matching CRISPR experimental design, this probabilistic framework provides estimates for essentiality with a robustness to experimental noise that misleads a straightforward averaging of the data (see Fig. 3 ). As our understanding of CRISPR mechanics continues to evolve, a simulation responsive to shifting sgRNA efficiencies and replicates occludes the necessity of excessive numbers of samples and controls.
As illustrated by the rapid evolution of 'core essential gene' sets over the past 10 years, the definition of 'essential' is a subjective and somewhat arbitrary classification. Essential gene candidates must be tested within each cell line, and then further validated through bespoke knockout experiments. Researchers should be cautious with relying upon published sets of 'essential' gene sets which have not been evaluated within their tissue type of interest, and carefully select the genetic background of the panel of samples used to evaluate essentiality. However, the case of differential essentiality is a relative metric, and will continue to be of interest to researchers exploring genetic vulnerabilities in cancer subtypes and tissue-specific metabolic networks.
Methods
Model Description. The core of our model is a series of Poisson sampling processes integrated over true sgRNA abundance, with a likelihood ratio test to evaluate significance. Essentiality estimates φ G ∈ [−∞, 1] are calculated for every genetic element G. Negative values of φ G indicate cells increase in abundance after perturbation of the genetic element; positive values indicate the element is essential for cell growth or proliferation. A graphical model representation of φ G is shown in Fig. 2 .
While sequenced read counts are usually modeled with a Negative Binomial distribution instead of Poisson (5, 30) , we introduce a similar level of overdispersion in our probability density during our integration over unobserved parameters (see Fig. S3 )).
The likelihood function used by ACE to derive parameters for gene essentiality φ G and sgRNA efficiency g is structured as follows, given master library sgRNA abundances m g , initial read counts x sg , total cells infected c s , and depleted read counts y sg :
Where n sg represents true number of cells infected with each sgRNA, and γ s and γ s are sample-specific scaling parameters. Each of the three sections of this likelihood represent an experimental stage in a CRISPR screen. The full likelihood is derived in the following sections.
CRISPR Master Library Normalization. When multiple replicates of the sgRNA master library are sequenced, we normalize each replicate by the total number of reads per sample and average across replicates. The resulting representation of relative master library frequencies, m g for sgRNA g, is used when modeling the infection of the master library. Alternatively condensed master library read counts may be submitted.
Infection of the sgRNA master library. The prior for the initial abundance n sg of sgRNA g within sample s is described by the following Poisson distribution. The mean µ 1 is determined by the experimentalist-reported total number of cells infected in our screen c s , and the relative frequency m g of each sgRNA g in the master library:
Because the number of infected cells n sg can not be directly observed, our model sums over the range of n sg ∈ [0, c s ]. This summation step is the major bottleneck in our code during parameter optimization, as it must be numerically evaluated for each sgRNA in every sample, and is approximated in intervals of 10 cells.
Initial read counts of sgRNA abundance. The sgRNA sequencing counts x sg from the initial infected population n sg are also modeled as a Poisson sampling process, with scaling parameter γ s per sample s absorbing the relationship between sequencing depth and number of cells infected:
Refinement of Sample Scaling Parameters. A change in sgRNA abundance across all sgRNAs within a sample can reflect any number of biological features, from the retardation of cell growth in the presence of Cas9 expression, to variation in passage number between screen designs. Our method addresses these factors, along with variation in sequencing depth, by scaling the number of infected cells n sg with sample parameters γ s and γ s , for the initial and final timepoint reads x sg and y sg respectively. These sample scaling parameters γ s and γ s are set according to the median ratio of counts per sample to a reference sgRNA abundance. The reference is set either using the frequency of sgRNAs in the master library, or the average abundance of each sgRNA in the initial samples (x sg ) if no master library is available. By default only sgRNAs targeting negative control genes (G neg ) are used to calculate this ratio, though the median ratio across all sgRNAs may be specified. This metric for read counts is then scaled by c s , the total number of cells in the experiment. The scaling factor for the final timepoint, γ s , is consequently calculated as follows:
In the case of uniformly essential libraries without negative controls and with identically efficient sgRNA, it is impossible to de-identify sample-specific effects from gene-specific essentiality without the use of positive controls with known values of essentiality.
Modeling sgRNA depletion. In a typical CRISPR negative selection screen, there are two rounds of sequencing. The first set of sequencing counts we model as a Poisson distribution, with a mean of µ 2 as described above. The second round of sequencing takes place after several cell divisions, allowing defects in cell growth and proliferation to manifest. For now, we assume that the abundance of a given sgRNA post depletion, d sg , reflects a deterministic process driven solely by the gene essentiality φ G of the genetic unit G targeted. In all screens examined in this paper, a single coding gene represents a genetic unit. An essentiality value of 0 corresponds with no effect on cell growth or proliferation. Negative essentiality is allowed by our model, observed as an increase in cell growth and proliferation due to perturbation of a deleterious genetic element.
Guide-specific Effects. This definition of µ 3 considers samplespecific and gene-specific depletion, but CRISPR screens are further affected by the efficiency of the sgRNA chosen. ACE calculates sgRNA-specific efficiency g from an independent categorical featureF . For our simulations, we used the decile of GC content for each sgRNA's template guide. Users may also derive a sgRNA categorical feature through an efficiency score formula such as those developed in (24, (31) (32) (33) (34) (35) . Guide efficiency g is derived from fitting weight ω f to the feature category F g of guide g:
Weight ω f is estimated by maximum likelihood across all guides within each category inF . This feature weight allows a fraction of the population of a sgRNA category to be active, but assumes the sgRNA within a particular cell will either be wholly successful or unsuccessful at disrupting its target element. Effective sgRNA drive cell depletion according to gene essentiality φ G , leading to our full description of µ 3 in Eq. (5) .
Full Model Likelihood. The full likelihood of the model takes into account all genes G, all sgRNA g within each gene, and all samples s.
Poiss n sg |c s m g Poiss x sg |γ s n sg
As φ G affects the likelihood of the observed counts x sg and y sg across all samples, sample scaling γ s influences all genes within each sample, and sgRNA efficiency weights g affect classes of sgRNA shared between all genes, concurrent numerical optimization of these three parameters must use data across all genes and samples simultaneously. For tractability with genome-wide screens, we infer φ G and g iteratively, permitting parallelization by gene and sgRNA efficiency class. We numerically optimize the following likelihoods to infer gene essentiality φ G and the weight ω f of each sgRNA efficiency category:
Weights ω f are initialized to treat all sgRNA as 100% effective for the first optimization of φ G . To evaluate whether the estimated value of φ G represents a significant essentiality, we compare this likelihood to L(φ G = 0) using a likelihood-ratio test. P-values for φ G are calculated empirically using a null distribution from the likelihood ratio values from negative control genes.
Adaptation to Experimental Design. Some CRISPR screens do not sequence their prepared master library, instead relying on initial and final sequencing to provide information on relative sgRNA abundances. Others do not sequence the initial pool of infected cells, and instead measure only the sgRNA present in the master library. For these experimental modifications, the modularity of our model is quite useful, allowing us to omit the portion of our likelihood for which we have no experimental data.
For experiments without master library information, we use a uniform prior for values of n sg , with our likelihood as fol-lows. Terms µ 2 and µ 3 are given in equations (3) and (5) respectively:
For experiments without sequencing of initial infected sgRNA abundances, we remove the portion of our likelihood addressing x sg :
Poiss n sg ; c s m g Poiss y sg ; µ 3
(11)
Identification of Subtype-Specific Genetic Vulnerabilities. To identify genes with significant differences in essentiality in one set of samples (s t ∈ S test ) as opposed to a contrasting panel (s c ∈ S ctrl ), we employ a simple likelihood ratio test for every gene G:
If the test statistic from this likelihood ratio falls significantly outside the empirical null distribution derived from the negative controls, and the associated φ test is significantly different from 0 according to Eq. (9), the gene is essential only in the samples within the test subset panel.
All samples are used to calculate sample-specific parameters γ s and γ s , sgRNA-specific parameter g , and gene essentiality parameter φ all G . Only φ G is re-estimated for the sample subsets to calculate φ test G and φ ctrl G ; estimates for all other parameters are held constant. Our model assumes constant g across all samples for all sgRNA with efficiency category F g .
CRISPR Screen Data and Essential Gene Sets.
The essential genes evaluated in Fig. S6 are analyzed using screen data from (19) . This experiment screened 5 AML cell lines with 2 replicates per cell line. Only the master library was sequenced, with no sgRNA counts from the initial infection. The genome-wide master library targets 18,010 genes with an average of 5 sgRNA designed per gene. Please see (19) for more experimental details; the CRISPR library is available through Addgene (ID 67989).
The set of essential genes used for validation was derived from the intersection of at least two of the datasets illustrated in Fig. 6 (1-3 ). The set of nonessential genes was obtained from 604 ENCODE total RNA-seq datasets for 128 cell lines, in vitro differentiated cells, primary cells, and tissues (see Supplemental Table 1 ). For the nonessential set, we chose genes expressed < 1 FPKM in all cell lines.
Simulation of CRISPR Knockout Screens. As core essential gene sets vary based on experimental design and even between publications (1) (2) (3) 9) , we developed a series of computational simulations to generate sgRNA read counts under different experimental conditions with known gene essentiality. Each gene was independently simulated using a series of normal distributions to represent each stage of a CRISPR knockout screen (infection, initial and final sequencing). Distribution parameters were tuned to match published CRISPR knockout screens from (16) (see S 2). Initial master library abundances were selected by sampling sgRNA libraries described above. The abundance of each sgRNA construct was assumed to be independent from all other sgRNA used in the experiment. Unless otherwise noted, simulations used 300 genes per essentiality value, 4 sgRNA per gene, and 3 samples.
Package Software. ACE is implemented as an R package (R 3.5.0, (36)) using the data.table (37) and R6 (38) packages. Optimization is performed using R's optim package with the 'Brent' method.
Estimation of Essentiality from Mean Log Fold Change.
For the 'average fold change' ('AFC') scores, a pseudocount of 0.5 is added to both initial (x sg ) and final (y sg ) read counts to prevent undefined values. Each sample is then normalized by the total read counts to a total of 10 million reads. After fold changes are calculated, values are adjusted according to the mean fold change in negative controls. Consistent with our ACE notation, essentiality estimates are represented on a continuous scale, where a value of zero has no impact on cell growth or proliferation. AFC = 1 − (0.5 + y sg )/ g (0.5 + y sg ) (0.5 + x sg )/ g (0.5 + x sg )
Estimation of Essentiality using BAGEL. Results using BAGEL: Bayesian Analysis of Gene Essentiality (1) were derived using software version 0.91 (last modified 09/2015). Simulation data was analyzed using 4% of genes as positive and negative controls, with simulated essentiality scores of 0.99 (99% depletion) and 0.05 (5% depletion) respectively. Differential essentiality was calculated as the difference of Bayes Factors between separate analysis of test and control sample panels, as performed in (1) . For the analysis of real data, we used all genes identified as essential or nonessential in our earlier analysis.
Estimation of Essentiality using JACKS. Results using JACKS: joint analysis of CRISPR/Cas9 knock-out screens (8) calculated p-values on test and control sample panels separately, using the built-in hierarchical prior option and the same negative control genes provided to other methods.
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